

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

#27
Jg
8/8/02
RECEIVED
TECH OFFICE 1600/2900
02 JUL 30 PM 2:39

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 01 2002

TECH OFFICE 1600/2900

Sir:

The references cited on attached PTOSB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

The Assignee of the instant application is a licensee of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Application No. 09/441,140 is cited in the PTO/SB/08A form attached hereto. U.S. Patent No. 5,688,651 was cited in the Supplemental IDS submitted August 25, 2000. At the Examiner's request, U.S. Patent No. 5,688,651 was cited a second time in the Supplemental IDS filed August 20, 2001.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no

08/08/2002 GTECHWEL 00000004 201430 09322289
01 FC:126 180.00 CH
inference should be made that the information and references cited are, or are considered to be material

to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that a fee of \$180.00 is required for submission of this statement, since it is being submitted after the first Office Action, but before the mailing of any final office action, a notice of allowance, or an action that otherwise closes prosecution. The Commissioner is authorized to deduct the \$180.00 fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf